Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Oncopeptides, Audiocast, Press Conference, 2026

By Inderes5/11/2026, 10:00 AM
Oncopeptides

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Sofia Heigis
00:00 - 17:44

Welcome to our conference on the decision to submit a Type II variation for Pepaxti in Europe. The purpose of this call is to give you a better understanding of why we, at this time, intend to submit a Type II variation to broaden the European indication for Pepaxti. What we need to achieve to ensure patients can benefit from this broadening of indication. What impact a successful journey can make for both patients, shareholders, and the company. Presenting today is Sofia Heigis, CEO of Oncopeptides AB, and with me I have Henrik Bergentoft, our CFO. We have this morning announced that Oncopeptides AB intends to expand the indication for Pepaxti in Europe by applying to the European Medicines Agency for a third-line indication in less refractory patients than our current label. An approved indication with granted market access is expected to double our addressable patient population and double the average number of treatment cycles per patient. We plan to send the application within the next few months, with a final European Commission decision expected in the first half of 2027. During approximately 15 minutes, I will walk through the strategic rationale, the potential impact and next steps. Maybe most importantly, I will also provide an historic context and go through the science that has led us to make this decision. I will aim to address the questions we have already received since the announcement this morning, but also encourage you to ask questions in the Q&A that will follow my presentation. The rationale behind our decision to move Pepaxti into the third-line treatment rests on four key pillars: market expansion, extended exposure, clinical value, and pricing viability. We aim to move into the third-line and reach less refractory patients, which would at least double the number of addressable patients in Europe. Clinical data demonstrates that treatment cycles in the third-line setting are expected to double on average compared to our current label. This submission is built on the Phase 3 OCEAN study data, which EMA previously deemed Approvable, and I will come back to that soon. What makes us take this decision now is that our assessment of the current treatment landscape indicates we can now expand without compromising our innovative price level. To give you a better understanding of this, let's take a step back to 2023. As some of you may know, Oncopeptides AB has previously received an approval from the EMA to move Pepaxti into the third line. At the time, we chose to withdraw that approval. If we had moved Pepaxti into the third line when we achieved the approval back in 2023. There would have been a high risk of ending up with a very low European reference price, which would not have been sustainable from many different perspectives; however, given the rapidly evolving Multiple Myeloma treatment landscape with multiple launches in earlier lines, we now see that the pricing landscape has evolved significantly between our 2023 analysis and our 2026 assessment. In 2023, the pricing anchor in the first market to negotiate that would have set the new European reference price would have been a single comparator in a list of drugs that was used in third line. Back then, the cheapest comparator was a generic drug, which would have been our price anchor, with several new immunotherapies being launched and implementation of combinations, including 3 to 4 drug classes, has moved the field and made the individual treatment in third line more differentiated. This has triggered the shift from a single comparator price anchor to a basket of drugs, meaning several different alternatives that are used today in the third-line setting. This market basket is a mix of different price levels and, on average, represents a higher comparative price point than in 2023, even though we have to negotiate new prices. We have moved from an unfavorable market access situation to a different environment that makes it worth trying once more to give patients the opportunity to receive Pepaxti in third line by applying for this Type II variation. So what is the business impact? It is important to note that we need to achieve both regulatory approval and subsequently succeed with price negotiations to harvest the value of broadening the indication. With that said, let's look at what we know about the potential. We may be able to unlock and, just as important, point out the current unknowns to conclude what the new Pepaxti potential could look like. Our current communicated market potential of 1.5 billion reflects the current fourth-line indication in triple-class refractory patients; expanding into the third line creates significant added potential through three multipliers. We see a two times multiplier in addressable patients and a two times multiplier in average number of treatment cycles per patient. The third multiplier, price, will have to be negotiated as we are reaching more patients. And this process is country-specific and looks different in all European countries, and also varies between our key markets, where we currently have a price set for the current label. So, while we know the addressable patient population and treatment pattern in the third line, we will not know the exact price until we have finalized new market access and pricing negotiation market by market. Now let's move away from the numbers for a while, and let's look at the scientific rationale behind our application for the Type II variation. This chart illustrates the typical journey of a multiple myeloma patient from initial diagnosis through successive relapses. And given all the new treatment options, Multiple Myeloma has become a marathon with many lines of treatment rather than a short sprint. Today, there is no cure for Multiple Myeloma, and as you can see, each relapse is accompanied by an increase in tumor burden, meaning that the tumor becomes more and more aggressive and difficult to treat. Partly triggered by that, the tumor has to fight against many different modes of action in earlier lines, which makes it a tough warrior and more and more difficult to beat. Our current indication is represented by the orange block on the far right, serving patients in advanced disease, specifically those in the fourth line of therapy and beyond who are triple class refractory. At this late stage, the disease burden has already undergone rapid acceleration, and the patients are commonly both old and frail due to tumor side effects from previous treatments and comorbidities. Our goal with this Type II variation is to move that orange block to the left, as shown here, and by expanding into the third line, we can treat patients earlier in their disease course. Now let me start to briefly run through the mode of action of our peptide drug conjugates and Pepaxti to ensure you fully understand how Pepaxti is offering something new and needed. The cleverness of the PDCs lies in their highly lipophilic nature, allowing them to rapidly and passively diffuse across the cell membrane. This means that there is no receptor binding, and we already at this stage, can address resistance to drugs that are dependent on receptor binding on the surface. To activate the killing of the cell inside the cell, the PDCs are rapidly cleaved by peptidases and esterases. These sisters are upregulated in certain tumor cells, such as Multiple Myeloma, meaning that more active substance is released inside of the tumor cells, which drives further influx of the PDC into those cells. And with this distribution, we spare the healthy cells. The cell undergoes apoptosis, or programmed cell death, by a dual mechanism of action, where the activated and now hydrophilic cytotoxic payload accumulates to a high concentration within the cell, leading to DNA damage in the cell nucleus as well as in the mitochondria. One common resistance mechanism is that DNA is repaired in the nucleus, and we have seen in clinic that we can overcome this type of resistance. And we do believe that this is due to the mitochondrial damage. This dual DNA damage seems to be unique for the PDCs compared to conventional alkylators. Finally, the PDC mode of action is completely independent of the immune system, meaning that Pepaxti is providing a new way to attack the tumor that works also in patients with an exhausted immune system. So, in short, a highly complementary mode of action to other drugs that can be used in third-line as well as in the fourth-line setting. Let's look at the broader treatment landscape across Europe to see how Pepaxti fits. As already mentioned, patients in the first and second line are exposed to standard classes of drugs, such as proteasome inhibitors, IMiDs, and anti-CD38 monoclonal antibodies, commonly in 3 to 4 drug combinations to hit the tumor hard early on. Novel immunotherapies, such as CAR T-cell therapy, are approved already from the second line, and there are more approvals underway, which means that patients may need a rest from immunotherapy to allow their immune system to recover. By the time a patient reaches the third line, the most common approach today is rechallenging with options from the same drug classes used in lines 1 to 2. This is where Pepaxti fits perfectly as a PDC. It provides a distinct T cell independent mode of action. Looking at Pepaxti. The positioning is in one way the same in both third and fourth line as it is in outpatient-friendly treatment with a manageable safety profile suitable for patients that are unable to receive immunotherapy. Its distinct PDC mode of action facilitates treatment continuity and makes it a suitable bridge between therapies, and it remains a proven alternative for patients who have relapsed both after Car-T and bispecific therapies. So in summary, before we get into the scientific data, our current indication is for patients who have received at least three prior lines and are triple class refractory. The potential future indication would target patients who have received at least two prior lines and are refractory to lenalidomide and the last line of therapy. This broader population allows us to bring the benefits of Pepaxti to patients earlier in their treatment journey. For our current label, our phase three OCEAN study served as the confirmatory study for Pepaxti. This study confirmed the efficacy and safety profiles that were initially observed in our pivotal Phase 2 Horizon study. The current label population is based on the HORIZON study, and the regulatory approval we are now intending to seek is in a patient population based on the OCEAN study. So let me explain that study in brief. The OCEAN study is a Phase 3 head-to-head study of melflufen or Pepaxti plus dexamethasone versus previous standard of care Pomalidomide plus dexamethasone, with the primary endpoint being Progression-Free Survival and secondary key endpoints being Overall Response Rate and Overall Survival. It was in the OCEAN study that we identified the subgroup of patients with the most positive benefit-risk profile from Pepaxti. We call this subgroup our target population, and it consists of patients who have either not undergone a stem cell transplantation, or who had a good result from the transplantation and experienced progression only after 36 months from the transplantation. This is the target group that serves as the foundation for our current label and will serve as the foundation for any potential future labels. Now, let's have a closer look at the OCEAN data. Our target population from the OCEAN study had logically fewer years since diagnosis and fewer previous lines of treatment, with a median of two. Importantly, they were less refractory than those in our current label, being less frail and with the opportunity to get longer treatment duration. Overall, this population is larger and represents a group that is less refractory, yet has developed an aggressive tumor that can benefit from the PDC mode of action, matching the unmet need. Pepaxti plus Dex demonstrated a significant increase in PFS with a median PFS of 9.3 months for Pepaxti compared to 4.6 months for Pomalidomide plus Dex. The hazard ratio for PFS was 0.58, with a significant p-value of 0.0001. We also saw a favorable overall survival trend of 23.6 months for Pepaxti plus Dex, versus 19.8 months for Pom plus Dex. Pepaxti significantly favored patients in the target population for confirmed response. The overall response rate was 42% for Pepaxti versus 26% for the comparator. In conclusion, the OCEAN study met its primary endpoint, safety was confirmed, and the overall benefit-risk profile in our target group of patients was positive. This was also the feedback from EMA on our first submission for a Type II variation. Before we conclude and open up for Q&A, let's take a look at the timeline and milestones. We expect to submit the Type II variation to EMA in the coming months. We will now prepare the regulatory documentation needed to submit the application. Initial regulatory feedback is anticipated in the second half of 2026, and the final decision from the European Commission is expected in the first half of 2027. Market access processes, including benefit assessment and price negotiations, can formally be initiated post European Commission decision. This process looks different in various markets, and we will update the market on more specifics as we proceed. So to conclude, Oncopeptides AB is continuously working to maximise our European sales potential. Expanding into the third line would double the addressable patient population and double the average number of treatment cycles. This means the expansion has the potential to reach more patients with longer treatment duration, which could generate value for both patients and shareholders. The expansion requires that we achieve regulatory approval and successful market access. We have taken the decision to initiate this process with the intention to submit a regulatory dossier in coming months. Our focus remains on our key markets for now. We will, of course, assess the impact of this decision on other markets, as a broader label could open doors beyond our current focus. Through our own commercialization partnerships or a combination. In closing, we are embarking on a new and broader path for Pepaxti, grounded in robust clinical evidence and supported by an unmet need. Thank you for listening, and I will now hand over to the moderator for any questions.

Operator
17:46 - 18:03

If you wish to ask a question, please dial Pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Richard Romanus from Redeye. Please go ahead.

Richard Romanus
18:06 - 18:12

Hello. I have a few questions just to start. Does this affect your financial targets?

Sofia Heigis
18:15 - 18:20

Thank you for the question. Maybe I'll hand over to you, Henrik. Would you like to respond?

Henrik Bergentoft
18:20 - 19:22

Yes, absolutely. Thank you for that question, Richard. And, well, the long story short is that we are not changing our financial target of being cash flow positive during 2027. But to give some more color to that, in order for us to adjust the financial target, we first need a successful regulatory process and clarity on all factors affecting the potential for Pepaxti. Now, we already know that an approved application for a broader indication would double the current addressable patient population for Pepaxti in Europe, and double the average number of treatment cycles for patients compared to the current label. What is unknown is the timeline and also the outcome of the market access process and price negotiations, which are both important factors. So again, we perfectly well understand your question. But at this moment we're not changing our guidelines of being cash flow positive during 2027.

Richard Romanus
19:24 - 19:52

All right. As I understand it, up until the fourth line, most treatments are combination treatments. So, do you? Would you use Pepaxti mainly as a bridge therapy then? Because I assume you would need additional studies to use it as a combination treatment. And except for dexamethasone. But you could add another thing to that combo.

Sofia Heigis
19:53 - 22:35

Yes. So, third-line treatment is not a simple approach, as the treatment, just as I mentioned during my presentation, has become so differentiated in the first and second lines, where combinations of both triplets and quadruplets are used. And now when you also start to use immunotherapy like CAR T therapy and eventually also bispecific antibodies already in the second line, the patient's profile will look more in the third line as it has been looking in the fourth line in the sense that there may be a need for one. Important to mention, then, is that a bridging therapy is not only a few cycles, but it is really about giving the patient a different mode of action that is complementary to immunotherapy, and that allows the patient's immune system to rest so it can recharge and then be responsive to immunotherapy again. It is important to mention that a bridging therapy is not only a few cycles, but it is really to give the patient a different mode of action that is complementary to immunotherapy, and that allows the patient's immune system to rest so it can recharge and then be responsive to immunotherapy again. So just to put some flavor on what would a bridge mean. So it can be quite long treatment still, even though it would be in the third line. When it comes to combining Pepaxti, you are right that it is a doublet that is Pepaxti plus dexamethasone. But we are still expanding our indication. And you are right that there are many combinations used, of course, in the third line. But if you look at the data, the efficacy data, the safety and tolerability data. I would argue that compared to other, let's say, similar combinations our doublet stands strong. Looking at the OCEAN data with a PFS of 9.3 months and the Overall Survival of 23 months if you compare to novel immunotherapy. It's of course less. But our idea is not to compete with novel immunotherapy. Should we then succeed to get into the third line? Should we then succeed in getting into the third line? So there is a quite clear position that has been evolving. And I think this position, listening to the scientific congresses and the current debate, is all about sequencing and how you ensure that the patient can get as many different treatments as possible in different lines to, of course, live as long as possible. So I hope that responds to your question. If not, feel free to ask if you have any further questions on that topic.

Richard Romanus
22:37 - 22:40

Yes, that makes sense. Thanks for answering my questions.

Sofia Heigis
22:41 - 22:42

Thank you so much, Richard.

Operator
22:46 - 23:08

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for written questions and closing comments.

Unknown 1
23:09 - 23:13

If there are no written questions. Back to you, Sofia, for closing remarks.

Sofia Heigis
23:14 - 23:26

Thank you to everyone that listened today. And of course, should there be any further questions, feel free to reach out to us. And with that, I wish you all a good day.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…